N-Power Medicine raises $32m Series B to expand community oncology trials
The company will grow its research network and extend prospective external control-arm programs into colorectal and prostate cancer.
Trial-grade comparison data from community care
N-Power Medicine links a community-oncology care network with clinical-trial data services for cancer drug developers. Its ProECA platform builds prospective external control arms from trial-grade information collected during routine treatment, giving sponsors a comparison group without enrolling every patient in a traditional trial arm.
The $32 million Series B will expand the oncology research network, deepen pharmaceutical partnerships and extend ProECA into colorectal and prostate cancer. The existing non-small-cell lung cancer program operates at more than 40 community sites. The model connects research with care delivered close to home while helping drug developers evaluate therapies with smaller or faster studies.
Use of funds
Scale community oncology research network
Deepen pharmaceutical partnerships
Expand ProECA programs into colorectal and prostate cancer